Virtual Biopharmaceuticals Summit 2022: Full meeting agenda for November 22
Scientists from AstraZeneca, Bayer, Eli Lilly, Janssen, Roche, and other leading biopharma companies present on the latest topics biotherapeutic research and development
15 Nov 2022
The full exciting schedule has been announced for the SelectScience® Virtual Biopharmaceuticals Summit, taking place on November 22, in partnership with BioPhorum. Featuring presentations from AstraZeneca, Bayer, Eli Lilly, Janssen: Pharmaceutical Companies of Johnson & Johnson, and Roche scientists among others, this free-to-attend online event offers an interactive forum for scientists and manufacturers to connect, showcase the latest research, and share cutting-edge technology solutions for biopharmaceuticals research and development.
You can look forward to topics including:
- Novel approaches for therapeutic monoclonal antibody discovery
- Streamlined methods for binding kinetics
- The latest trends in cell and gene therapy
- Mass spectrometry techniques for oligonucleotides and larger nucleic acids
- The latest in adeno-associated viruses (AAVs) critical quality attribute (CQA) analysis
- Pharmaceutical compliance, and much more
The Summit will host talks by world-leading scientists, live Q&As, video interviews, interactive resource booths, and unique networking opportunities. Attendees will also be able to view academic and industry posters submitted by our global scientific community, leave comments, ask questions, and prompt collaboration through 1-on-1 chat facilities.
Register now to catch the talks that are most relevant to your work, and read on to learn more about:
Keynote speakers
- Paul Anderson, Director, Biologics Discovery Automation, Eli Lilly
- Dr. Andrew Mahan, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson
Agenda
Tuesday, November 22
The Summit sessions take place in two concurrent tracks. Track 1 talks cover a range of topics in both Cell Line Development and Gene Therapy, while Track 2 is focused on Bioanalysis techniques. Times in bold are shown as Greenwich Mean Time (GMT).
11:30
12:30 (CET)
06:30 (EST)
03:30 (PST)
Opening address & Poster session
12:00
13:00 (CET)
07:00 (EST)
04:00 (PST)
Analysis of critical quality attributes of adeno-associated viruses (AAVs)
Dr. Farihah Haque, Product Specialist for GPC/SEC, Tosoh Bioscience
Pharma compliance
David Grant, Global Product Manager, ELGA LabWater
12:45
13:45 (CET)
07:45 (EST)
04:45 (PST)
Applying a matrix approach for potency assay development for in vivo and ex vivo gene therapies
Dominic Hildebrand, Head of Laboratory / QC & Analytical Development, Bayer
Shihua Lin, Pharmaceutical R&D Scientist, AstraZeneca
Sarah Currie, Account Manager, BioPhorum
Biolayer interferometry as an alternative to surface plasmon resonance in a biopharma regulated environment
Dr. Arnaud Delobel, R&D and Innovation Director, Strategy & Innovation, Quality Assistance S.A.
13:15
14:15 (CET)
08:15 (EST)
05:15 (PST)
Semi-targeted spent media LC-MS assay: Assuring product quality during cell line development for biologics
Keynote: Dr. Andrew Mahan, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson
14:00
15:00 (CET)
09:00 (EST)
06:00 (PST)
Go beyond titer and select top producers with favorable quality attributes within 5 days of cloning
Dr. Aurora Fabry-Wood, Product Manager, Cell Line Development, Berkeley Lights
15:00
16:00 (CET)
10:00 (EST)
07:00 (PST)
Single cell antibody discovery using ‘Islands of automation'
Keynote: Paul Anderson, Director - Biologics Discovery Automation at Eli Lilly
Recent advances in oligo purity and sequence determination by LCMS: Maximizing throughput, confidence, and coverage
Dr. Peter Rye, Application Engineer, Agilent Technologies
15:45
16:45 (CET)
10:45 (EST)
07:45 (PST)
Virtual coffee break - Connect with fellow attendees
16:05
17:05 (CET)
11:05 (EST)
08:05 (PST)
User stories for IT to support cell and gene therapies
David Wallace, Facilitator, BioPhorum
Doan Chau, Global Industry Technical Consultant, Rockwell Automation
Sean Buckley, Chief Information Officer, Immunocore
Fred Dardy, IT Portfolio Architect - Architecture & Emerging Technologies Chapter – PTIX, Roche
Christian Hoferer, Team Head MES & Serialization, Roche
Kim Wilson, Life Sciences Business Consultant, Dassault Systèmes
Developing methods for biosimilarty studies of therapeutic monoclonal antibodies
Dr. Kalhari Silva, Head of Scientific Innovation and Research, Custom Biologics
16:50
17:50 (CET)
11:50 (EST)
08:50 (PST)
A mid-down strategy for the mass spectrometric sequencing of progressively larger nucleic acids
Dr. Dan Fabris, Harold S. Schwenk Sr. Distinguished Chair in Chemistry, University of Connecticut
17:05
18:05 (CET)
12:05 (EST)
09:05 (PST)
Release specifications for plasmids and master cell banks used in gene therapy
Dr. Basak Clements, Associate Director, Janssen: Pharmaceutical Companies of Johnson & Johnson
17:35
18:35 (CET)
12:35 (EST)
09:35 (PST)
Ligand binding assay validation requirements and strategies
Mark Dysinger, Associate Director, Alexion Pharmaceuticals
17:50
18:50 (CET)
12:50 (EST)
09:50 (PST)
Cell and gene therapy validation challenges
Dr. Sharif Ahmed, Director, Process Validation - Global MSAT-Biotech, Bayer
18:35
19:35 (CET)
13:35 (EST)
10:35 (PST)
Poster session
Sponsors
Register for free to reserve a place today — you’ll be able to drop in and out as you wish during the Summit.
Watch this space for further updates and follow our social media channels:
Spread the word using #BiopharmaSummit
Catch up on the latest techniques and technologies and play your part in improving science communication by leaving a lab product review.